Integra LifeSciences traded at $11.26 this Friday February 6th, increasing $0.38 or 3.49 percent since the previous trading session. Looking back, over the last four weeks, Integra LifeSciences gained 14.37 percent. Over the last 12 months, its price fell by 55.35 percent. Looking ahead, we forecast Integra LifeSciences to be priced at 10.80 by the end of this quarter and at 9.83 in one year, according to Trading Economics global macro models projections and analysts expectations.
Integra LifeSciences Holdings Corporation provides regenerative technologies and neurosurgical solutions. The Company offers a portfolio of brands including AmnioExcel, Bactiseal, Certas, Codman, CUSA, DuraGen, DuraSeal, ICP Express, Integra, MediHoney, MicroFrance, PriMatrix, SurgiMend, TCC-EZ, and VersaTru. The Company offers solutions in orthopedics, neurosurgery, and reconstructive and general surgery. The Company operates through two segments: Codman Specialty Surgical segment, and Orthopedics and Tissue Technologies segment. The Codman Specialty Surgical segment includes the Neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care. The Orthopedics and Tissue Technologies segment includes such offerings as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair products.